CN Patent

CN102037123A — Epas1抑制剂的组合物和用途

Assigned to Calando Pharmaceuticals Inc · Expires 2011-04-27 · 15y expired

What this patent protects

本发明涉及内皮PAS结构域蛋白1(EPAS1)的抑制剂以及与EPAS1抑制剂相关的方法和组合物。在某些实施方案中，EPAS1抑制剂包括核酸，例如siRNA。

USPTO Abstract

本发明涉及内皮PAS结构域蛋白1(EPAS1)的抑制剂以及与EPAS1抑制剂相关的方法和组合物。在某些实施方案中，EPAS1抑制剂包括核酸，例如siRNA。

Drugs covered by this patent

Patent Metadata

Patent number
CN102037123A
Jurisdiction
CN
Classification
—
Expires
2011-04-27
Drug substance claim
No
Drug product claim
No
Assignee
Calando Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.